We claim:

- 1. A pharmaceutical dosage form comprising a plurality of pellets, wherein each pellet comprises:
 - a pellet core having a diameter within the range of 0.1 to 1.5 mm and comprising tamsulosin or a pharmaceutically acceptable salt thereof, an inert pellet forming carrier, a release control agent and optionally water;
 and
 - b. an outer layer coat surrounding said core which comprises a pharmaceutically acceptable acid-resistant polymer, wherein the mass of said outer layer coat, calculated on a dry pellet core basis, is within the range of 1-25 %; and

wherein the plurality of pellets exhibits a dissolution release profile in simulated gastric fluid using Ph. Eur. basket method at 100 rpm which includes releasing less than 25 % of the tamsulosin or salt thereof during the first two hours.

- 2. The dosage form according to claim 1, wherein the tamsulosin is a salt selected from the group consisting of tamsulosin hydrochloride, hydrobromide, sulfate, phosphate, acetate, propionate, maleate, fumarate, malonate, lactate, citrate, tartrate, mesylate, and besylate.
- 3. The dosage form according to claim 2, wherein the tamsulosin salt is tamsulosin hydrochloride.
- 4. The dosage form according to claim 1, wherein the amount of the tamsulosin or salt thereof in the pellet core is equivalent to 0.05-5.0 mass % of tamsulosin hydrochloride, calculated on a dry pellet core basis.
- 5. The dosage form according to claim 1, wherein the pellet forming carrier comprises a material selected from the group consisting of microcrystalline cellulose, alpha lactose, dextrin, mannitol, chitosan, and combinations thereof.

- 6. The dosage form according to claim 5, wherein said pellet forming carrier is microcrystalline cellulose.
- 7. The dosage form according to claim 5, wherein the amount of the pellet forming carrier is 50-95 mass %, calculated on a dry pellet core basis.
- 8. The dosage form according to claim 1, wherein the release control agent comprises a pharmaceutically acceptable polymer.
- 9. The dosage form according to claim 8, wherein the pharmaceutically acceptable polymer is selected from the group consisting of acrylic polymers, cellulose derivatives, and combinations thereof.
- 10. The dosage form according to claim 9, wherein the pharmaceutically acceptable polymer is a water permeable acrylic polymer.
- 11. The dosage form according to claim 8, wherein the amount of the release control agent is from 1-25 mass%, calculated on a dry pellet core basis.
- 12. The dosage form according to claim 1, wherein the content of water in the pellet core is from 2 to 10 %, calculated on a dry pellet core basis.
- 13. The dosage form according to claim 1, wherein the diameter of the dried pellet core is within the range from 0.3 to 0.9 mm
- 14. The dosage form according to claim 1, wherein the acid-resistant polymer comprises an acid-resistant acrylic polymer.
- 15. The dosage form according to claim 14, wherein the release control agent in the pellet core is the same as the acid-resistant acrylic polymer in the outer coat.
- 16. The dosage form according to claim 14, wherein the outer layer coat comprises 25-75 mass % of the acid-resistant acrylic polymer, calculated on a dry basis.
- 17. The dosage form according to claim 1, wherein said mass of the outer layer coat, calculated on a dry pellet core basis, is within the range of 2.5-15 mass %.

- 18. The dosage form according to claim 1, wherein the dissolution release profile in simulated gastric fluid includes releasing less than 15% of tamsulosin during the first two hours in Ph. Eur. basket apparatus at 100 rpm.
- 19. The dosage form according to claim 1, wherein the plurality of pellets exhibit a dissolution release profile in a phosphate buffer of pH 6.8 using Ph. Eur. basket method at 100 rpm which includes releasing:

10-50% of the tamsulosin in 30 minutes, and/or

25-75% of the tamsulosin in one hour, and/or more than 70% of the tamsulosin in five hours.

- 20. The dosage form according to claim 1, wherein the dosage form is a capsule or sachet.
- 21. The dosage form according to claim 20, wherein the amount of tamsulosin or salt thereof contained in the pellet is equivalent to 0.1 to 1 mg of tamsulosin hydrochloride.
- 22. A process for making the dosage form according to claim 1, which comprises:
 - a. granulating a mixture of tamsulosin or a pharmaceutically acceptable salt thereof, a pellet forming carrier, a release control agent, a granulation liquid comprising water, and optionally auxiliary ingredients to form wet pellet cores;
 - b. drying said wet pellet cores;
- c. selecting said dried pellet cores to obtain a fraction within the size range of 0.1-1.5 mm;
- d. coating said selected dried pellet cores with a coating composition, which comprises an acid-resistant polymer and which is sufficient to provide said dried coated pellet with 1 to 25 mass % of said coating composition, calculated on the dry pellet core basis.; and
 - e. drying said coated pellet.

- 23. The process according to claim 22, wherein the tamsulosin is a salt selected from the group consisting of tamsulosin hydrochloride, hydrobromide, sulfate, phosphate, acetate, propionate, maleate, fumarate, malonate, lactate, citrate, tartrate, mesylate, and besylate.
- 24. The process according to claim 23, wherein the amount of the tamsulosin salt in the pellet core, is equivalent to 0.05-5.0 mass % of tamsulosin hydrochloride, calculated on a dry pellet core basis.
- 25. The process according to claims 22, wherein the pellet forming carrier comprises a material selected from the group consisting of microcrystalline cellulose, alpha lactose, dextrin, mannitol, chitosan and combination thereof.
- 26. The process according to claim 22, wherein the pharmaceutically acceptable polymer is a water permeable acrylic polymer.
- 27. The process according to claim 22, wherein the content of water in the pellet core after drying is from 2 to 10 %, calculated on a dry pellet core basis.
- 28. The process according to claim 22, wherein the selection of the pellet core fraction is performed by sieving.
- 29. The process according to claim 28, wherein the diameter of the dried pellet core is within the range from 0.3 to 0.9 mm.
- 30. The process according to claim 22, wherein the mass of the outer layer coat, calculated on a dry pellet core basis, is within the range of 2.5-15 mass %.
- 31. The process according to claim 22, wherein said coating step (d) is performed in a high shear mixer/granulator.
- 32. The process according to claim 22, wherein said coating step (d) is performed in a fluid bed coater.
- 33. The process according to claim 22, wherein said coating step (d) is performed on a coating pan.

- 34. A process for making a pharmaceutical dosage form, which comprises the steps of:
 - a. granulating a mixture of tamsulosin or a pharmaceutically acceptable salt thereof, a pellet forming carrier, a release control agent, a granulation liquid comprising water, and optionally auxiliary ingredients to form wet pellet cores;
 - b. drying said wet pellet cores;
- c. selecting said dried pellet cores to obtain a fraction within the size range of 0.1-1.5 mm;
- d. coating said selected dried pellet cores with a coating composition, which comprises an acid-resistant polymer;
 - e. drying said coated pellet;
- f. testing a sample of said dried coated pellets for dissolution rate in a simulated gastric fluid; and
- (g) repeating the coating process on the remaining dried coated pellets until a desired rate of release is achieved in said testing step (f).
- 35. The process according to claim 34, wherein the desired rate of release includes less than 25% of the tamsulosin during the first two hours.
- 36. A method for treating the symptoms of benign prostatic hyperplasia, which comprises administering an effective amount of the pellets according to claim 1, to a patient in need thereof.